Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection DOI Creative Commons
Veronika Vaňová, Jana Náhliková, Martina Ličková

et al.

Viruses, Journal Year: 2025, Volume and Issue: 17(5), P. 675 - 675

Published: May 6, 2025

Understanding the long-term dynamics of SARS-CoV-2 neutralizing antibodies is critical for evaluating vaccine-induced protection and informing booster strategies. In this longitudinal study, we analyzed 114 serum samples from 19 individuals across six time points over a three-year period following mRNA vaccination (Comirnaty) natural infection. Using pseudotype-based neutralization assays against nine variants, including major Omicron subvariants (BA.1–BA.5, BQ.1.1, XBB), anti-S1 IgG ELISA, observed that antibody levels peaked after third vaccine dose remained relatively stable two years later. Neutralization titers rose markedly second doses, with highest at post-booster. Strong correlations were found between mean pre-Omicron variants (r = 0.79–0.93; p < 0.05), but only moderate ≈ 0.50–0.64). Notably, hybrid immunity (vaccination plus infection) resulted in higher final point compared to vaccine-only participants. The lowest was XBB, underscoring immune evasiveness emerging variants. These findings support importance highlight added durability protection.

Language: Английский

Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection DOI Creative Commons
Veronika Vaňová, Jana Náhliková, Martina Ličková

et al.

Viruses, Journal Year: 2025, Volume and Issue: 17(5), P. 675 - 675

Published: May 6, 2025

Understanding the long-term dynamics of SARS-CoV-2 neutralizing antibodies is critical for evaluating vaccine-induced protection and informing booster strategies. In this longitudinal study, we analyzed 114 serum samples from 19 individuals across six time points over a three-year period following mRNA vaccination (Comirnaty) natural infection. Using pseudotype-based neutralization assays against nine variants, including major Omicron subvariants (BA.1–BA.5, BQ.1.1, XBB), anti-S1 IgG ELISA, observed that antibody levels peaked after third vaccine dose remained relatively stable two years later. Neutralization titers rose markedly second doses, with highest at post-booster. Strong correlations were found between mean pre-Omicron variants (r = 0.79–0.93; p < 0.05), but only moderate ≈ 0.50–0.64). Notably, hybrid immunity (vaccination plus infection) resulted in higher final point compared to vaccine-only participants. The lowest was XBB, underscoring immune evasiveness emerging variants. These findings support importance highlight added durability protection.

Language: Английский

Citations

0